In order to improve ER+ breast cancer treatment, a combination of endocrine therapies with other compounds, such as CDK4/6 inhibitors, mTOR inhibitors, PI3K inhibitors, and AR antagonists, are under investigation. This evidence concerns the gene AR and breast cancer.